{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:51:18Z","timestamp":1780404678524,"version":"3.54.1"},"reference-count":74,"publisher":"Informa UK Limited","issue":"30","funder":[{"name":"AMGEN GmbH; Celgene GmbH;"},{"name":"BristolMyers Squibb GmbH and Janssen GmbH"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,12,31]]},"DOI":"10.2217\/fon-2018-0040","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T10:53:50Z","timestamp":1532948030000},"page":"3123-3134","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["The Role of Carfilzomib in Treatment of Newly Diagnosed Multiple Myeloma"],"prefix":"10.1080","volume":"14","author":[{"given":"Susanne","family":"Strifler","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology & Medical Oncology, Wuerzburg University Medical Center, Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Hematology & Medical Oncology, Wuerzburg University Medical Center, Wuerzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,7,30]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"e_1_3_3_4_1","unstructured":"Howlader N NooneA KrapchoMet al. SEER Cancer Statistics Review 1975\u20132012. Based on November 2014 SEER data submission posted to the SEER web site April 2015. National Cancer Institute MD USA (2015). http:\/\/seer.cancer.gov\/csr\/1975_2012\/."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-201053"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14304"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-693580"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0023"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0755"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3007"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0822"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-425934"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414359"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.29"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-511170"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.743.743"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12878-016-0053-9"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563759"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.74.74"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0782"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3531"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2258"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.047662"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4086"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422683"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2010"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4527.4527"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.675.675"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1142.1142"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.05.009"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.327"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4739.4739"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.8003"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.8004"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-626168"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_3_3_43_1","article-title":"Phase 3 study (CLARION) of carfilzomib, melphalan, prednisone (KMP) v bortezomib, melphalan, prednisone (VMP) in newly diagnosed multiple myeloma (NDMM)","author":"Facon T","year":"2017","unstructured":"Facon T , LeeJH, MoreauP. Phase 3 study (CLARION) of carfilzomib, melphalan, prednisone (KMP) v bortezomib, melphalan, prednisone (VMP) in newly diagnosed multiple myeloma (NDMM). Presented at: 16th International Myeloma Workshop. 1\u20134 March, New Delhi, India, (2017).","journal-title":"Presented at: 16th International Myeloma Workshop. 1\u20134 March, New Delhi, India"},{"issue":"1","key":"e_1_3_3_44_1","first-page":"3110","article-title":"Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open-label, Phase 1b study","volume":"130","author":"Chari A","year":"2017","unstructured":"Chari A , UsmaniSZ, KrishnanAet al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open-label, Phase 1b study. Blood130(Suppl. 1), 3110\u20133110 (2017).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_3_45_1","first-page":"3141","article-title":"Carfilzomib combined with thalidomide and low-dose dexamethasone for remission induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma: the Carthadex trial","volume":"130","author":"Wester R","year":"2017","unstructured":"Wester R , van derH, oltB, AsselbergsEet al. Carfilzomib combined with thalidomide and low-dose dexamethasone for remission induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma: the Carthadex trial. Blood130(Suppl. 1), 3141\u20133141 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13296"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-576256"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089334"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12877"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.346"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1950"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-016-9378-7"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000183"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14708"},{"key":"e_1_3_3_58_1","first-page":"e174519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","author":"Waxman A","year":"2017","unstructured":"Waxman A , ClasenS, HwangW, AlE. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol.e174519 (2017).","journal-title":"JAMA Oncol."},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-915"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12677"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2014.11.008"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.93"},{"issue":"102","key":"e_1_3_3_63_1","article-title":"Incidence and risk factors of cardiovascular adverse events in a large population of newly diagnosed, transplant-ineligible myeloma patients treated with carfilzomib","volume":"102","author":"Bringhen S","year":"2017","unstructured":"Bringhen S , MinaR, PetrucciMTet al. Incidence and risk factors of cardiovascular adverse events in a large population of newly diagnosed, transplant-ineligible myeloma patients treated with carfilzomib. Haematologica102(102), Abstract E1247 (2017).","journal-title":"Haematologica"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.03.012"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1403020"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716667275"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12749"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.4250.4250"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0040-1"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683854"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.222"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3160"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14920"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:08Z","timestamp":1719125108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,30]]},"references-count":74,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2018,12,31]]}},"alternative-id":["10.2217\/fon-2018-0040"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0040","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}